Market in sight for Pharmaxis
Wednesday, 20 August, 2008
Pharmaxis [ASX: PXS] has concluded a Phase 3 clinical trial of its Bronchitol treatment, confirming its safety in subjects with bronchiectasis.
None of the 99 subjects who concluded the trial experienced serious adverse effects attributable to the drug, even after a 12-month treatment schedule.
Some minor side effects were attributable to the medication, such as coughing and a sore throat, but these symptoms occurred in less than 10 per cent of the sample group.
Seven subjects did drop out of the trial after suffering adverse events – lung infections or chronic coughing – but it has not been demonstrated that Bronchitol was the cause of these effects.
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
